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The immune system attempts to prevent or limit Results and discussion
Angiogenesis, migration, and host immune defences aretumor growth, yet efforts to induce responses to
tumors yield minimal results, rendering tumors the fundamental components on which the outcome of
the metastatic process depends; all three are largely che-virtually invisible to the immune system [1]. Several
mechanisms may account for this subversion, mokine-controlled [6, 7]. Chemokines not only govern
events that are critical for tumor cell migration, such asincluding the triggering of tolerance to tumor
antigens [2, 3], TGF-a or IL-10 production, cell polarization, but also display autocrine properties [8].
By promoting the migration of appropriate cells into tis-downregulation of MHC molecules, or
upregulation of FasL expression [4, 5]. Melanoma sues or creating the architecture that facilitates cell inter-
cells may in some instances use FasL expression
to protect themselves against tumor-infiltrating
lymphocytes (TIL) [4, 5]. Here, we show another,
Figure 1chemokine-dependent mechanism by which
melanoma tumor cells shield themselves from
immune reactions. Melanoma-inducible CCL5
(RANTES) production by infiltrating CD8 cells
activates an apoptotic pathway in TIL involving
cytochrome c release into the cytosol and
activation of caspase-9 and -3. This process,
triggered by CCL5 binding to CCR5, is not mediated
by TNFa, Fas, or caspase-8. The effect is not unique
to CCL5, as other CCR5 ligands such as CCL3 (MIP-
1a) and CCL4 (MIP-1b) also trigger TIL cell death,
nor is it limited to melanoma cells, as it also
operates in activated primary T lymphocytes. The
model assigns a role to the CXC chemokine
CXCL12 (SDF-1a) in this process, as this melanoma
cell-produced chemokine upregulates CCL5
production by TIL, initiating TIL cell death.
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Melanoma induces TIL cell death. (a) TIL were cultured in RPMI, AIM-V,
or conditioned medium (CM) from SK29-MEL or MEL#1 cells or
Published: 1 May 2001 cocultured with SK29-MEL or MEL#1 melanoma cells. After 24 hr,
the cell cycle stage was analyzed by PI staining and flow cytometry.
Histograms show relative DNA content versus cell number; the
Current Biology 2001, 11:691–696 percentage of cells in the sub-G1 phase is shown. The figure depicts
one representative experiment of the five performed. (b) Whole-mount
TUNEL on TIL, MEL#1 cells, or the SK29-MEL cell line. Nuclear0960-9822/01/$ – see front matter
staining with Hoechst is shown in blue; apoptosis is detected as red
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staining.
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Figure 2
Chemokine expression by primary melanoma
cells and TIL. (a) Chemokine expression in
48 hr-conditioned medium from established
melanomas, melanoma cell lines, and TIL
were analyzed for CCL2, 3, 5, and CXCL12
production. Results show the mean 6 SD of
triplicates from one representative experiment
of the five performed. (b) CCL5 production
by TIL that were stimulated 48 hr with
conditioned medium from primary MEL#1
melanoma, SK29-MEL cells, or chemokines
(CCl2 and CXCL12) was assessed. CCL5
concentration in AIM-V medium and CCL5
upregulation in unstimulated TIL that were
cultured for 48 hr (Medium) are shown as
controls. The effect of anti-CXCL12 antibody
on melanoma-induced chemokine
upregulation is shown.
action and successful immune responses, they collaborate A major conundrum in cancer is that the presence of TIL
does not result in cancer cell elimination [3]. We used ato establish the conditions that precede the immune re-
sponse [9]. human malignant melanoma model to study the mecha-
nisms underlying the lack of tumor rejection. Melanoma
lines and infiltrating CD81 T cells from several melanomaCCL5 is a chemokine that interacts with the G protein-
coupled receptors (GPCR) CCR1, CCR3, CCR4, and patients were derived in vitro. TIL that were cultured in
the presence of melanoma cells underwent cell death, asCCR5 [11]. It is a potent chemoattractant for CD41 and
CD81 lymphocytes as well as for monocytes, NK cells, assessed by cellular DNA staining with the DNA interca-
lator propidium iodide (PI), and evaluation of the percent-and eosinophils [11]. A close relationship has been estab-
lished between the induction of HIV-1-specific cytotoxic- age of DNA in the hypodiploid subG0/G1 cell cycle peak
(Figure 1a) or by the detection of apoptotic nuclei usingity and the CCL5 effect via CCR3 [12, 13]. In addition,
using human peripheral blood lymphocytes (PBL), malig- TUNEL (terminal deoxynucleotidyl transferase-medi-
ated dUTP nick end labeling) after Hoechst staining (Fig-nant T cells, and CD4/CXCR4 transfectants, the active
role of CXCR4 has been described in the rapid, CD95- ure 1b). Cell death is observed 16 hr after the initiation
of coculture, reaching a maximum at 48 hr. TIL deathindependent cell death of CD41 T cells [14]. Increased
CCL5 expression by breast carcinomas correlates with requires the presence of freshly explanted melanomas,
since culture-adapted melanoma lines, such as SK29-enhanced tumor progression [15]. These studies suggest
that chemokines also participate in activating the apo- MEL, are unable to trigger apoptosis (Figures 1a,b and
S1a). Similar results were obtained in experiments usingptotic cell death pathway. Here, we establish a link be-
tween the ability of chemokines to promote tumor pro- primary melanoma cell lines derived from seven patients.
To determine whether tumor-TIL cell contact was neces-gression and the prevention of tumor elimination by the
immune system. The results show CXCL12-mediated sary, experiments were performed using conditioned me-
dium from a melanoma cell line (SK29-MEL) or freshupregulation of CCL5 production by TIL. CCL5 binding
to CCR5 promotes specific CCR5 cell death via activation melanoma cells (MEL#1) to induce TIL cell death. No
significant cell death was observed when SK29-MEL-of a cytochrome c-dependent pathway in the infiltrating
cells, the consequence of which is tumor cell escape from conditioned medium was used, whereas MEL#1-condi-
tioned medium induced cell death levels similar to thoseimmune system control.
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Figure 3induced by TIL coculture with fresh melanoma cells (Fig-
ure 1a). No apoptosis was detected following TIL culture
in fresh medium for the same period, indicating that the
effect was due to a melanoma cell-released factor(s) in
the medium.
Melanoma cells trigger CCL5 production
by infiltrating lymphocytes
To characterize the molecules involved in this type of
cell death, we analyzed surface proteins on TIL and mela-
nomas. Using specific antibodies in flow cytometry, we
detected Fas, TNFR-II, and TNF-a levels in both cell
types, whereas no significant staining was seen using
TNFR-I- and FasL-specific antibodies (Figure S1b). Fur-
ther characterization included chemokine receptors and
melanoma-specific markers. Neither TIL nor melanoma
cells express surface CCR2, but both express CXCR4, and
a significant percentage of the TIL population (30%–56%)
expresses CCR5 (see Supplementary material).
This receptor expression pattern prompted analysis of the
chemokines produced by both TIL and melanoma cells,
as chemokines have been implicated in tumor growth
[16]. Primary melanoma cells from several patients, but
not the established melanoma cell lines SK-MEL-28,
SK29-MEL, or A-375, produced elevated CCL2 (MCP-1)
and CXCL12 levels, whereas TIL produced CCL3, 4,
and 5 (Figure 2a). This data was supported by the finding
that TIL cocultures with fresh melanoma cells, but not
with SK29-MEL or its conditioned medium, upregulated
TIL CCL5 production (Figure 2b). In determining whether
the melanoma-produced chemokines were responsible for
this effect, we found that CXCL12 (5 nM), but not CCL2
(5 nM), also upregulates CCL5 production by TIL (Fig-
ure 2b). This finding concurs with the blocking effect
of anti-CXCL12 antibodies on MEL#1-promoted CCL5
upregulation (Figure 2b). All together, these data suggest
CCL5 induces cell death in TIL and PBL through a CCR5- and Gthat melanoma-secreted CXCL12 is responsible for the
protein-dependent mechanism. (a) Melanoma-conditioned medium-upregulation of CCL5 production and subsequent effects. induced TIL death is blocked by preincubation with met-RANTES or
with neutralizing anti-CCR5 (CCR5–01), -CCL5, or -CXCL12 mAb.
(b) TIL were incubated with the indicated chemokine (24 hr, 378C),As chemokines may have a role similar to that described
and the percentage of cell death was analyzed. (c) CCL5- and
for CCL5-induced cell death in HIV-1-infected T cells CCL3-induced TIL cell death is blocked by incubation with neutralizing
[12, 13], we attempted to identify the mechanisms by anti-CCR5 mAb (CCR5–01). (d) TIL were treated with PTx or AG-
490 prior to incubation with conditioned medium from primarywhich melanoma cells trigger TIL death. Melanoma-con-
melanoma or SK29-MEL cells. (a–d) show the mean 6 SD of theditioned, medium-induced TIL death was blocked by a
percentage of cells in the sub-G1 phase. (e) The effect of CCL5CCL5 antagonist (met-RANTES, 10 nM) by neutralizing treatment on cell death in CCR51-activated PBL, determined by CCR5/
anti-CCL5 (10 mg/ml) or anti-CCR5 (CCR5–01, 20 mg/ annexin V double staining in flow cytometry. The figure shows the
percentage of annexin V-positive cells in CCR51 or CCR52 PBLml) mAb, but not by isotype-matched control mAb (Fig-
after CCL5 stimulation (10 nM, 24 hr), alone or in the presence ofure 3a). Neutralizing anti-CXCL12 antibody also blocks
antagonists (anti-CCL5 mAb or met-RANTES).TIL death, indicating a CXCL12-induced, CCR5-medi-
ated mechanism compatible with CXCL12-induced CCL5
upregulation. To further correlate cell death with chemo-
kine production, TIL were incubated (24 hr) with several or 5 induced cell death (Figure 3b), which is blocked
by neutralizing anti-CCR5 mAb (Figure 3c). CXCL12concentrations (1–10 nM) of CXCL12 or CCL2, 3, 4, or
5. Whereas CCL2 did not promote cell death, incubation induced moderate TIL death (10%–15%) at 24 hr, which
increased thereafter (Figure 3b). Finally, the cell deathfor 24 hr with the CCR5-related chemokines CCL3, 4,
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Figure 4 triggered by MEL#1 and TIL coculture is blocked by
anti-CXCL12 antibody and reconstituted by exogenous
CCL5 addition (data not shown).
CCL5 triggers an apoptotic pathway involving
cytochrome c release from mitochondria
as well as caspase-8 and -3 activation
CCL5 signaling is mediated by triggering receptor homo-
dimerization, which recruits the JAK1 tyrosine kinase, and
subsequent association of the Gai protein to the receptor
complex [17]. Blocking this signal by treatment of TIL
with pertussis toxin (PTx, which arrests Gai protein acti-
vation) or AG-490 (which inhibits JAK activation) pre-
vents cell death induced by CCL5 or by melanoma-condi-
tioned medium (Figure 3d). This indicates that both Gai
protein and JAK kinase activation are required to induce
specific CCL5-mediated cell death in TIL, as neither
PTx nor AG-490 block Fas ligation-induced cell death
(data not shown). We thus conclude that the melanoma
induces death in TIL by activating CCL5 production; this
chemokine triggers an apoptotic pathway that requires
chemokine receptor activation. This pathway is not exclu-
sive to TIL but can also be triggered in PBL, in which
CCL5 promotes specific depletion of CCR5-expressing
cells, as determined by CCR5/annexin V staining (Figure
3e). This depletion is blocked by neutralizing anti-CCL5
Ab, anti-CCR5 mAb, or met-RANTES (Figure 3e).
Two main mechanisms have been proposed for apoptosis
triggering; first, caspase-8 recruitment to death receptors
(Fas or TNF) and second, cytochrome c release from
mitochondria to the cytosol, followed by Apaf-1 recruit-
ment, which activates caspase-9 and leads to cell death
[18]. When TIL were maintained in culture, cytochrome
c was localized in mitochondria (Figure 4a), whereas when
these cells were incubated with CCL5 or melanoma-con-
ditioned medium, cytochrome c was released to the cyto-
sol, as detected by immunofluorescence (Figure 4a) or
Western blot (Figure 4b). As expected in the cytochrome
c pathway, caspase-9 was activated, which is shown by
the presence of the cleaved 30 kDa form (Figure 4c, upper
panel), as was caspase 3, which is shown by the presence
of the 17 kDa cleaved form (Figure 4c, middle panel).
Caspase-8 activation was not detected in CCL5-induced
cell death (Figure 4c, lower panel). We thus conclude that,
CCL5 induces cytochrome c release and caspase-3 and -9 activity. in TIL, CCL5 activates an apoptotic pathway triggered by(a) TIL, unstimulated or stimulated with CCL5 (10 nM, 24 hr), were
cytochrome c release from mitochondria, which involvesfixed, permeabilized, and stained with anti-cytochrome c or anti-
mitochondria antibodies (see Supplementary material). The figure caspase-9 and -3 activation. This concurs with results in
shows specific staining of mitochondria (green), cytochrome c (red), apoptotic pathway activation via another chemokine re-
and a computer overlay of both images (yellow). (b) TIL were CCL5- ceptor, CXCR4 [14].stimulated (10 nM) for the times indicated. After washing,
mitochondria-free cellular extracts were prepared as indicated (see
Materials and methods), electrophoresed, transferred to nitrocellulose
membranes, and the Western blot was analyzed with anti-
positive control in the anti-caspase-3 and -8 Western blots, Jurkatcytochrome c mAb. The membrane was stripped and reprobed with
cells were stimulated with anti-human Fas mAb (CH11), and cellanti-actin antibody as a protein loading control. (c) TIL as in (b) were
lysates were analyzed as indicated above.analyzed in Western blot with anti-caspase-9, -3, or -8 antibodies. The
loading equivalence was controlled using a protein detection kit. As a
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Supplementary materialHere, we describe a mechanism that operates through
Detailed information on antibodies employed, flow cytometry, immunoflu-caspase-9 and -3, is independent of caspase-8 activation,
orescence, Western blot analysis, and other techniques can be found
and is engaged by melanoma cells to escape immune at http://images.cellpress.com/supmat/supmatin.htm.
rejection. This pathway appears to be triggered by cyto-
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